In addition, the phase 1 U31402-A-U103 (NCT04676477) dose-escalation and -expansion study is evaluating HER3-DXd in combination with osimertinib in first- and second-line settings for EGFR-mutated NSCLC, exploring innovative combinatory strategies to circumvent resistance [181]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.